세계의 결막염 치료 시장 규모, 점유율, 동향 분석 리포트 : 질환 유형별, 약제 클래스별, 유통 채널별, 지역별 전망과 예측(2023-2030년)

Global Conjunctivitis Treatment Market Size, Share & Trends Analysis Report By Disease Type, By Drug Class (Anti-allergic, Antiviral, Artificial Tears, and Antibiotics), By Distribution Channel, By Regional Outlook and Forecast, 2023 - 2030

US $ 3,600 ￦ 5,023,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,320 ￦ 6,028,000

PDF (Multi User License)

PDF 보고서를 동일 기업의 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,048 ￦ 8,439,000

PDF (Corporate User License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

결막염 치료 시장 규모는 예측 기간 중 CAGR 4.7%로 성장하며, 2030년까지 61억 달러에 달할 것으로 예측됩니다.

그러나 항생제 내성 박테리아의 증식은 세균성 결막염을 치료하기 위해 항생제를 부적절하게 사용하거나 과도하게 사용했기 때문일 수 있습니다. 이는 일반적으로 사용되는 항생제의 효과가 시간이 지남에 따라 감소하여 세균 감염 치료에 어려움을 겪을 수 있음을 의미합니다. 항생제 내성은 세균성 결막염 치료에 효과적인 항생제의 범위를 좁힙니다. 내성이 확산되면 사용 가능한 치료 옵션이 줄어들고 기존 항생제로 감염을 관리하기가 더 어려워집니다. 또한 항생제 내성은 치료 실패의 위험을 증가시킵니다. 원인균이 일반적으로 처방되는 항생제에 내성을 가지면 감염이 지속되어 해결되지 않은 증상과 잠재적인 합병증을 유발할 수 있습니다.

목차

제1장 시장 범위와 조사 방법

• 시장의 정의
• 목적
• 시장 범위
• 세분화
• 조사 방법

제2장 시장 요약

• 주요 하이라이트

제3장 시장 개요

• 서론
  • 개요
    • 시장 구성과 시나리오
• 시장에 영향을 미치는 주요 요인
  • 시장 촉진요인
  • 시장 억제요인
  • 시장 기회
  • 시장이 해결해야 할 과제
• Porter's Five Forces 분석

제4장 세계 시장 : 질환 유형별

• 세계의 알레르기성 결막염 시장 : 지역별
• 세계의 바이러스성 결막염 시장 : 지역별
• 세계의 세균성 결막염 시장 : 지역별

제5장 세계 시장 : 약제 클래스별

• 세계의 항알레르기약시장 : 지역별
• 세계의 항바이러스 시장 : 지역별
• 세계의 인공눈물 시장 : 지역별
• 세계의 항생제 시장 : 지역별

제6장 세계 시장 : 유통 채널별

• 세계의 병원 약국 시장 : 지역별
• 세계의 소매 약국 시장 : 지역별
• 세계의 온라인 약국 시장 : 지역별

제7장 세계 시장 : 지역별

• 북미의 시장
  • 북미의 시장 : 질환 유형별
  • 북미의 시장 : 약제 클래스별
  • 북미의 시장 : 유통 채널별
  • 북미의 시장 : 국가별
    • 미국의 결막염 치료 시장
    • 캐나다의 결막염 치료 시장
    • 멕시코의 결막염 치료 시장
    • 기타 북미의 시장
• 유럽의 시장
  • 유럽의 시장 : 질환 유형별
  • 유럽의 시장 : 약제 클래스별
  • 유럽의 시장 : 유통 채널별
  • 유럽의 시장 : 국가별
    • 독일의 결막염 치료 시장
    • 영국의 결막염 치료 시장
    • 프랑스의 결막염 치료 시장
    • 러시아의 결막염 치료 시장
    • 스페인의 결막염 치료 시장
    • 이탈리아의 결막염 치료 시장
    • 기타 유럽의 시장
• 아시아태평양의 시장
  • 아시아태평양의 시장 : 질환 유형별
  • 아시아태평양의 시장 : 약제 클래스별
  • 아시아태평양의 시장 : 유통 채널별
  • 아시아태평양의 시장 : 국가별
    • 중국의 결막염 치료 시장
    • 일본의 결막염 치료 시장
    • 인도의 결막염 치료 시장
    • 한국의 결막염 치료 시장
    • 싱가포르의 결막염 치료 시장
    • 말레이시아의 결막염 치료 시장
    • 기타 아시아태평양의 시장
• 라틴아메리카·중동 및 아프리카의 시장
  • 라틴아메리카·중동 및 아프리카의 시장 : 질환 유형별
  • 라틴아메리카·중동 및 아프리카의 시장 : 약제 클래스별
  • 라틴아메리카·중동 및 아프리카의 시장 : 유통 채널별
  • 라틴아메리카·중동 및 아프리카의 시장 : 국가별
    • 브라질의 결막염 치료 시장
    • 아르헨티나의 결막염 치료 시장
    • UAE의 결막염 치료 시장
    • 사우디아라비아의 결막염 치료 시장
    • 남아프리카공화국의 결막염 치료 시장
    • 나이지리아의 결막염 치료 시장
    • 기타 라틴아메리카·중동 및 아프리카의 시장

제8장 기업 개요

• Novartis AG
• Gilead Sciences, Inc
• GlaxoSmithKline PLC
• F Hoffmann-La Roche Ltd.
• Merck & Co, Inc.
• Boehringer Ingelheim International GmbH
• AbbVie, Inc
• AFT Pharmaceuticals
• Bausch Health Companies, Inc
• Teva Pharmaceutical Industries Ltd

제9장 결막염 치료 시장의 성공 필수 조건

KSA

영문 목차

영문목차

The Global Conjunctivitis Treatment Market size is expected to reach $6.1 billion by 2030, rising at a market growth of 4.7% CAGR during the forecast period.

Environmental allergens, viral infections, and other triggers contribute to a consistent demand for conjunctivitis treatment across the region. Therefore, the Nort America region captured $1,583.6 million revenue in the market in 2022. North America has a thriving pharmaceutical research and development (R&D) sector, with domestic and multinational pharmaceutical companies conducting innovative research in various therapeutic areas. According to Statistics Canada, in 2020, the R&D pharmaceutical sector contributed $15.9 billion to the Canadian economy in GVA, an increase of 5.8% from the $15.0 billion generated in 2019. The sector's direct impacts accounted for slightly less than half of this amount ($7.9 billion), an increase of 4.5% compared to the $7.6 billion produced in 2019. Indirect impacts accounted for 28.3% of the total GVA in 2020 and increased 6.1% to $4.5 billion, while induced impacts advanced 8.7% to $3.5 billion.

Higher healthcare expenditure often translates into improved access to healthcare services, including eye care. Individuals with conjunctivitis are more likely to seek medical attention and receive timely diagnosis and treatment when healthcare services are readily accessible. Increased healthcare spending allows for the adoption and integration of advanced medical technologies in diagnosing and treating conjunctivitis. Advanced diagnostic tools and treatment modalities contribute to more accurate assessments and effective management of the condition. Additionally, Improved awareness about the symptoms of conjunctivitis prompts individuals to seek medical attention at the early stages of the condition. The implementation of treatment in a punctual manner is facilitated by an early diagnosis, which prevents the development of conjunctivitis and mitigates the intensity of symptoms. Healthcare providers and organizations engage in community outreach programs to disseminate information about eye health. These programs may include eye screenings, educational seminars, the distribution of informational materials, and the raising of awareness about conjunctivitis and available treatments. These initiatives often include campaigns that highlight the importance of eye health and prompt individuals to seek appropriate treatment for eye conditions. Therefore, the rising awareness about eye health is driving the growth of the market.

However, the proliferation of antibiotic-resistant bacterial strains may result from the improper or excessive use of antibiotics to treat bacterial conjunctivitis. This means that the effectiveness of commonly used antibiotics diminishes over time, leading to challenges in treating bacterial infections. Antibiotic resistance narrows the range of effective antibiotics available for treating bacterial conjunctivitis. As resistance spreads, fewer viable treatment options may be available, making it difficult to manage infections with traditional antibiotics. Additionally, antibiotic resistance increases the risk of treatment failure. In cases where the causative bacteria are resistant to commonly prescribed antibiotics, the infection may persist, leading to unresolved symptoms and potential complications.

By Disease Analysis

On the basis of disease type, the market is segmented into allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. The allergic conjunctivitis segment recorded the largest revenue share in the market in 2022. The surge in allergic conjunctivitis cases drives an increased demand for anti-allergic medications in the market. The rising impact of allergic conjunctivitis prompts innovation in drug delivery systems within the market. This includes the development of advanced eye drop formulations, sustained-release technologies, and other delivery methods to enhance the efficacy and duration of anti-allergic medications.

By Drug Class Analysis

Based on drug class, the market is divided into antibiotics, antiviral, anti-allergic, and artificial tears. In 2022, the anti-allergic segment garnered the highest revenue share in the market. Anti-allergic drugs, particularly antihistamines and mast cell stabilizers, are applied to provide symptomatic relief from common allergic conjunctivitis symptoms. These symptoms include itching, redness, tearing, and swelling. Antihistamines, which block the effects of histamine released during an allergic reaction, are a primary application in allergic conjunctivitis. These drugs help alleviate itching and reduce the overall inflammatory response.

By Distribution Channel Analysis

Based on distribution channel, the market is categorized into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment witnessed a noteworthy revenue share in the market in 2022. Retail pharmacies are often conveniently located in community settings, making them easily accessible to patients. This accessibility is crucial for individuals seeking over the counter (OTC) medications or prescription drugs for without the need for a hospital visit. Many cases of conjunctivitis, especially mild and uncomplicated forms, can be managed with over-the-counter medications. Retail pharmacies provide a wide range of OTC eye drops and treatments, allowing individuals to engage in self-care and promptly address mild symptoms without needing a healthcare provider visit.

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region generated a substantial revenue share in the market. The Asia Pacific region is characterized by high population density, with a substantial number of people residing in urban and densely populated areas. This population density contributes to a higher prevalence of infectious diseases, including conjunctivitis, leading to an increased demand for treatment. Environmental factors like air pollution, dust, and exposure to allergens are prevalent in many parts of Asia Pacific. These environmental conditions can contribute to conjunctivitis, particularly allergic conjunctivitis, driving the demand for treatments to manage eye-related symptoms.

Recent Strategies Deployed in the Market

• 2022-Dec: Merck & Co., Inc. came into partnership with Astellas Pharma Inc., a pharmaceutical manufacturing company, and Seagen Inc., a biotechnology research company. Through this partnership, Merck & Co., Inc. would provide initial treatment for specific individuals diagnosed with locally advanced or metastatic urothelial cancer.
• 2021-May: Teva Pharmaceutical Industries Ltd. Introduced "250 mg and 500 mg strength generic Erythromycin tablets". The Erythromycin tablets are employed to treat infections caused by particular, susceptible strains of microorganisms in various diseases.
• 2021-Apr: Teva Pharmaceutical Industries Ltd. Introduced "10 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg strength generic version of Absorica®1 (isotretinoin) capsules" in the United States. The products are available for the treatment of severe recalcitrant nodular acne in patients 12 Years of age and older.
• 2020-Oct: GlaxoSmithKline (GSK) plc reported that the European Commission has given its approval for Zejula (niraparib), a PARP inhibitor taken orally once a day. This approval is specifically for its use as a first-line monotherapy maintenance treatment for adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube, or primary peritoneal cancer, who have achieved complete or partial response following platinum-based chemotherapy.
• 2019-Feb: Bausch Health Companies, Inc. took over Eton Pharmaceuticals Inc., a US-based pharmaceutical manufacturing company. Through this acquisition, Bausch Health Companies, Inc. would enhance its business of eye health products.

List of Key Companies Profiled

• Novartis AG
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Boehringer Ingelheim International GmbH
• AbbVie, Inc.
• AFT Pharmaceuticals
• Bausch Health Companies, Inc.
• Teva Pharmaceutical Industries Ltd.

Global Conjunctivitis Treatment Market Report Segmentation

By Disease Type

• Allergic Conjunctivitis
• Viral Conjunctivitis
• Bacterial Conjunctivitis

By Drug Class

• Anti-allergic
• Antiviral
• Artificial Tears
• Antibiotics

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Conjunctivitis Treatment Market, by Disease Type
  • 1.4.2 Global Conjunctivitis Treatment Market, by Drug Class
  • 1.4.3 Global Conjunctivitis Treatment Market, by Distribution Channel
  • 1.4.4 Global Conjunctivitis Treatment Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market at a Glance

• 2.1 Key Highlights

Chapter 3. Market Overview

• 3.1 Introduction
  • 3.1.1 Overview
    • 3.1.1.1 Market Composition and Scenario
• 3.2 Key Factors Impacting the Market
  • 3.2.1 Market Drivers
  • 3.2.2 Market Restraints
  • 3.2.3 Market Opportunities
  • 3.2.4 Market Challenges
• 3.3 Porter Five Forces Analysis

Chapter 4. Global Conjunctivitis Treatment Market, by Disease Type

• 4.1 Global Allergic Conjunctivitis Market, by Region
• 4.2 Global Viral Conjunctivitis Market, by Region
• 4.3 Global Bacterial Conjunctivitis Market, by Region

Chapter 5. Global Conjunctivitis Treatment Market, by Drug Class

• 5.1 Global Anti-allergic Market, by Region
• 5.2 Global Antiviral Market, by Region
• 5.3 Global Artificial Tears Market, by Region
• 5.4 Global Antibiotics Market, by Region

Chapter 6. Global Conjunctivitis Treatment Market, by Distribution Channel

• 6.1 Global Hospital Pharmacy Market, by Region
• 6.2 Global Retail Pharmacy Market, by Region
• 6.3 Global Online Pharmacy Market, by Region

Chapter 7. Global Conjunctivitis Treatment Market, by Region

• 7.1 North America Conjunctivitis Treatment Market
  • 7.1.1 North America Conjunctivitis Treatment Market, by Disease Type
    • 7.1.1.1 North America Allergic Conjunctivitis Market, by Country
    • 7.1.1.2 North America Viral Conjunctivitis Market, by Country
    • 7.1.1.3 North America Bacterial Conjunctivitis Market, by Country
  • 7.1.2 North America Conjunctivitis Treatment Market, by Drug Class
    • 7.1.2.1 North America Anti-allergic Market, by Country
    • 7.1.2.2 North America Antiviral Market, by Country
    • 7.1.2.3 North America Artificial Tears Market, by Country
    • 7.1.2.4 North America Antibiotics Market, by Country
  • 7.1.3 North America Conjunctivitis Treatment Market, by Distribution Channel
    • 7.1.3.1 North America Hospital Pharmacy Market, by Country
    • 7.1.3.2 North America Retail Pharmacy Market, by Country
    • 7.1.3.3 North America Online Pharmacy Market, by Country
  • 7.1.4 North America Conjunctivitis Treatment Market, by Country
    • 7.1.4.1 US Conjunctivitis Treatment Market
      • 7.1.4.1.1 US Conjunctivitis Treatment Market, by Disease Type
      • 7.1.4.1.2 US Conjunctivitis Treatment Market, by Drug Class
      • 7.1.4.1.3 US Conjunctivitis Treatment Market, by Distribution Channel
    • 7.1.4.2 Canada Conjunctivitis Treatment Market
      • 7.1.4.2.1 Canada Conjunctivitis Treatment Market, by Disease Type
      • 7.1.4.2.2 Canada Conjunctivitis Treatment Market, by Drug Class
      • 7.1.4.2.3 Canada Conjunctivitis Treatment Market, by Distribution Channel
    • 7.1.4.3 Mexico Conjunctivitis Treatment Market
      • 7.1.4.3.1 Mexico Conjunctivitis Treatment Market, by Disease Type
      • 7.1.4.3.2 Mexico Conjunctivitis Treatment Market, by Drug Class
      • 7.1.4.3.3 Mexico Conjunctivitis Treatment Market, by Distribution Channel
    • 7.1.4.4 Rest of North America Conjunctivitis Treatment Market
      • 7.1.4.4.1 Rest of North America Conjunctivitis Treatment Market, by Disease Type
      • 7.1.4.4.2 Rest of North America Conjunctivitis Treatment Market, by Drug Class
      • 7.1.4.4.3 Rest of North America Conjunctivitis Treatment Market, by Distribution Channel
• 7.2 Europe Conjunctivitis Treatment Market
  • 7.2.1 Europe Conjunctivitis Treatment Market, by Disease Type
    • 7.2.1.1 Europe Allergic Conjunctivitis Market, by Country
    • 7.2.1.2 Europe Viral Conjunctivitis Market, by Country
    • 7.2.1.3 Europe Bacterial Conjunctivitis Market, by Country
  • 7.2.2 Europe Conjunctivitis Treatment Market, by Drug Class
    • 7.2.2.1 Europe Anti-allergic Market, by Country
    • 7.2.2.2 Europe Antiviral Market, by Country
    • 7.2.2.3 Europe Artificial Tears Market, by Country
    • 7.2.2.4 Europe Antibiotics Market, by Country
  • 7.2.3 Europe Conjunctivitis Treatment Market, by Distribution Channel
    • 7.2.3.1 Europe Hospital Pharmacy Market, by Country
    • 7.2.3.2 Europe Retail Pharmacy Market, by Country
    • 7.2.3.3 Europe Online Pharmacy Market, by Country
  • 7.2.4 Europe Conjunctivitis Treatment Market, by Country
    • 7.2.4.1 Germany Conjunctivitis Treatment Market
      • 7.2.4.1.1 Germany Conjunctivitis Treatment Market, by Disease Type
      • 7.2.4.1.2 Germany Conjunctivitis Treatment Market, by Drug Class
      • 7.2.4.1.3 Germany Conjunctivitis Treatment Market, by Distribution Channel
    • 7.2.4.2 UK Conjunctivitis Treatment Market
      • 7.2.4.2.1 UK Conjunctivitis Treatment Market, by Disease Type
      • 7.2.4.2.2 UK Conjunctivitis Treatment Market, by Drug Class
      • 7.2.4.2.3 UK Conjunctivitis Treatment Market, by Distribution Channel
    • 7.2.4.3 France Conjunctivitis Treatment Market
      • 7.2.4.3.1 France Conjunctivitis Treatment Market, by Disease Type
      • 7.2.4.3.2 France Conjunctivitis Treatment Market, by Drug Class
      • 7.2.4.3.3 France Conjunctivitis Treatment Market, by Distribution Channel
    • 7.2.4.4 Russia Conjunctivitis Treatment Market
      • 7.2.4.4.1 Russia Conjunctivitis Treatment Market, by Disease Type
      • 7.2.4.4.2 Russia Conjunctivitis Treatment Market, by Drug Class
      • 7.2.4.4.3 Russia Conjunctivitis Treatment Market, by Distribution Channel
    • 7.2.4.5 Spain Conjunctivitis Treatment Market
      • 7.2.4.5.1 Spain Conjunctivitis Treatment Market, by Disease Type
      • 7.2.4.5.2 Spain Conjunctivitis Treatment Market, by Drug Class
      • 7.2.4.5.3 Spain Conjunctivitis Treatment Market, by Distribution Channel
    • 7.2.4.6 Italy Conjunctivitis Treatment Market
      • 7.2.4.6.1 Italy Conjunctivitis Treatment Market, by Disease Type
      • 7.2.4.6.2 Italy Conjunctivitis Treatment Market, by Drug Class
      • 7.2.4.6.3 Italy Conjunctivitis Treatment Market, by Distribution Channel
    • 7.2.4.7 Rest of Europe Conjunctivitis Treatment Market
      • 7.2.4.7.1 Rest of Europe Conjunctivitis Treatment Market, by Disease Type
      • 7.2.4.7.2 Rest of Europe Conjunctivitis Treatment Market, by Drug Class
      • 7.2.4.7.3 Rest of Europe Conjunctivitis Treatment Market, by Distribution Channel
• 7.3 Asia Pacific Conjunctivitis Treatment Market
  • 7.3.1 Asia Pacific Conjunctivitis Treatment Market, by Disease Type
    • 7.3.1.1 Asia Pacific Allergic Conjunctivitis Market, by Country
    • 7.3.1.2 Asia Pacific Viral Conjunctivitis Market, by Country
    • 7.3.1.3 Asia Pacific Bacterial Conjunctivitis Market, by Country
  • 7.3.2 Asia Pacific Conjunctivitis Treatment Market, by Drug Class
    • 7.3.2.1 Asia Pacific Anti-allergic Market, by Country
    • 7.3.2.2 Asia Pacific Antiviral Market, by Country
    • 7.3.2.3 Asia Pacific Artificial Tears Market, by Country
    • 7.3.2.4 Asia Pacific Antibiotics Market, by Country
  • 7.3.3 Asia Pacific Conjunctivitis Treatment Market, by Distribution Channel
    • 7.3.3.1 Asia Pacific Hospital Pharmacy Market, by Country
    • 7.3.3.2 Asia Pacific Retail Pharmacy Market, by Country
    • 7.3.3.3 Asia Pacific Online Pharmacy Market, by Country
  • 7.3.4 Asia Pacific Conjunctivitis Treatment Market, by Country
    • 7.3.4.1 China Conjunctivitis Treatment Market
      • 7.3.4.1.1 China Conjunctivitis Treatment Market, by Disease Type
      • 7.3.4.1.2 China Conjunctivitis Treatment Market, by Drug Class
      • 7.3.4.1.3 China Conjunctivitis Treatment Market, by Distribution Channel
    • 7.3.4.2 Japan Conjunctivitis Treatment Market
      • 7.3.4.2.1 Japan Conjunctivitis Treatment Market, by Disease Type
      • 7.3.4.2.2 Japan Conjunctivitis Treatment Market, by Drug Class
      • 7.3.4.2.3 Japan Conjunctivitis Treatment Market, by Distribution Channel
    • 7.3.4.3 India Conjunctivitis Treatment Market
      • 7.3.4.3.1 India Conjunctivitis Treatment Market, by Disease Type
      • 7.3.4.3.2 India Conjunctivitis Treatment Market, by Drug Class
      • 7.3.4.3.3 India Conjunctivitis Treatment Market, by Distribution Channel
    • 7.3.4.4 South Korea Conjunctivitis Treatment Market
      • 7.3.4.4.1 South Korea Conjunctivitis Treatment Market, by Disease Type
      • 7.3.4.4.2 South Korea Conjunctivitis Treatment Market, by Drug Class
      • 7.3.4.4.3 South Korea Conjunctivitis Treatment Market, by Distribution Channel
    • 7.3.4.5 Singapore Conjunctivitis Treatment Market
      • 7.3.4.5.1 Singapore Conjunctivitis Treatment Market, by Disease Type
      • 7.3.4.5.2 Singapore Conjunctivitis Treatment Market, by Drug Class
      • 7.3.4.5.3 Singapore Conjunctivitis Treatment Market, by Distribution Channel
    • 7.3.4.6 Malaysia Conjunctivitis Treatment Market
      • 7.3.4.6.1 Malaysia Conjunctivitis Treatment Market, by Disease Type
      • 7.3.4.6.2 Malaysia Conjunctivitis Treatment Market, by Drug Class
      • 7.3.4.6.3 Malaysia Conjunctivitis Treatment Market, by Distribution Channel
    • 7.3.4.7 Rest of Asia Pacific Conjunctivitis Treatment Market
      • 7.3.4.7.1 Rest of Asia Pacific Conjunctivitis Treatment Market, by Disease Type
      • 7.3.4.7.2 Rest of Asia Pacific Conjunctivitis Treatment Market, by Drug Class
      • 7.3.4.7.3 Rest of Asia Pacific Conjunctivitis Treatment Market, by Distribution Channel
• 7.4 LAMEA Conjunctivitis Treatment Market
  • 7.4.1 LAMEA Conjunctivitis Treatment Market, by Disease Type
    • 7.4.1.1 LAMEA Allergic Conjunctivitis Market, by Country
    • 7.4.1.2 LAMEA Viral Conjunctivitis Market, by Country
    • 7.4.1.3 LAMEA Bacterial Conjunctivitis Market, by Country
  • 7.4.2 LAMEA Conjunctivitis Treatment Market, by Drug Class
    • 7.4.2.1 LAMEA Anti-allergic Market, by Country
    • 7.4.2.2 LAMEA Antiviral Market, by Country
    • 7.4.2.3 LAMEA Artificial Tears Market, by Country
    • 7.4.2.4 LAMEA Antibiotics Market, by Country
  • 7.4.3 LAMEA Conjunctivitis Treatment Market, by Distribution Channel
    • 7.4.3.1 LAMEA Hospital Pharmacy Market, by Country
    • 7.4.3.2 LAMEA Retail Pharmacy Market, by Country
    • 7.4.3.3 LAMEA Online Pharmacy Market, by Country
  • 7.4.4 LAMEA Conjunctivitis Treatment Market, by Country
    • 7.4.4.1 Brazil Conjunctivitis Treatment Market
      • 7.4.4.1.1 Brazil Conjunctivitis Treatment Market, by Disease Type
      • 7.4.4.1.2 Brazil Conjunctivitis Treatment Market, by Drug Class
      • 7.4.4.1.3 Brazil Conjunctivitis Treatment Market, by Distribution Channel
    • 7.4.4.2 Argentina Conjunctivitis Treatment Market
      • 7.4.4.2.1 Argentina Conjunctivitis Treatment Market, by Disease Type
      • 7.4.4.2.2 Argentina Conjunctivitis Treatment Market, by Drug Class
      • 7.4.4.2.3 Argentina Conjunctivitis Treatment Market, by Distribution Channel
    • 7.4.4.3 UAE Conjunctivitis Treatment Market
      • 7.4.4.3.1 UAE Conjunctivitis Treatment Market, by Disease Type
      • 7.4.4.3.2 UAE Conjunctivitis Treatment Market, by Drug Class
      • 7.4.4.3.3 UAE Conjunctivitis Treatment Market, by Distribution Channel
    • 7.4.4.4 Saudi Arabia Conjunctivitis Treatment Market
      • 7.4.4.4.1 Saudi Arabia Conjunctivitis Treatment Market, by Disease Type
      • 7.4.4.4.2 Saudi Arabia Conjunctivitis Treatment Market, by Drug Class
      • 7.4.4.4.3 Saudi Arabia Conjunctivitis Treatment Market, by Distribution Channel
    • 7.4.4.5 South Africa Conjunctivitis Treatment Market
      • 7.4.4.5.1 South Africa Conjunctivitis Treatment Market, by Disease Type
      • 7.4.4.5.2 South Africa Conjunctivitis Treatment Market, by Drug Class
      • 7.4.4.5.3 South Africa Conjunctivitis Treatment Market, by Distribution Channel
    • 7.4.4.6 Nigeria Conjunctivitis Treatment Market
      • 7.4.4.6.1 Nigeria Conjunctivitis Treatment Market, by Disease Type
      • 7.4.4.6.2 Nigeria Conjunctivitis Treatment Market, by Drug Class
      • 7.4.4.6.3 Nigeria Conjunctivitis Treatment Market, by Distribution Channel
    • 7.4.4.7 Rest of LAMEA Conjunctivitis Treatment Market
      • 7.4.4.7.1 Rest of LAMEA Conjunctivitis Treatment Market, by Disease Type
      • 7.4.4.7.2 Rest of LAMEA Conjunctivitis Treatment Market, by Drug Class
      • 7.4.4.7.3 Rest of LAMEA Conjunctivitis Treatment Market, by Distribution Channel

Chapter 8. Company Profiles

• 8.1 Novartis AG
  • 8.1.1 Company Overview
  • 8.1.2 Financial Analysis
  • 8.1.3 Segmental and Regional Analysis
  • 8.1.4 Research & Development Expense
  • 8.1.5 SWOT Analysis
• 8.2 Gilead Sciences, Inc.
  • 8.2.1 Company overview
  • 8.2.2 Financial Analysis
  • 8.2.3 Research & Development Expenses
  • 8.2.4 SWOT Analysis
• 8.3 GlaxoSmithKline PLC
  • 8.3.1 Company Overview
  • 8.3.2 Financial Analysis
  • 8.3.3 Regional Analysis
  • 8.3.4 Research & Development Expense
  • 8.3.5 Recent strategies and developments:
    • 8.3.5.1 Trial and Approval
  • 8.3.6 SWOT Analysis
• 8.4 F. Hoffmann-La Roche Ltd.
  • 8.4.1 Company Overview
  • 8.4.2 Financial Analysis
  • 8.4.3 Segmental and Regional Analysis
  • 8.4.4 Research & Development Expense
  • 8.4.5 SWOT Analysis
• 8.5 Merck & Co., Inc.
  • 8.5.1 Company Overview
  • 8.5.2 Financial Analysis
  • 8.5.3 Segmental and Regional Analysis
  • 8.5.4 Research & Development Expenses
  • 8.5.5 Recent strategies and developments:
    • 8.5.5.1 Partnerships, Collaborations, and Agreements:
  • 8.5.6 SWOT Analysis
• 8.6 Boehringer Ingelheim International GmbH
  • 8.6.1 Company Overview
  • 8.6.2 Financial Analysis
  • 8.6.3 Regional & Segmental Analysis
  • 8.6.4 Research & Development Expenses
  • 8.6.5 SWOT Analysis
• 8.7 AbbVie, Inc.
  • 8.7.1 Company Overview
  • 8.7.2 Financial Analysis
  • 8.7.3 Regional Analysis
  • 8.7.4 Research & Development Expense
  • 8.7.5 SWOT Analysis
• 8.8 AFT Pharmaceuticals
  • 8.8.1 Company Overview
  • 8.8.2 Financial Analysis
  • 8.8.3 Segmental Analysis
  • 8.8.4 Research & Development Expenses
  • 8.8.5 SWOT Analysis
• 8.9 Bausch Health Companies, Inc
  • 8.9.1 Company Overview
  • 8.9.2 Financial Analysis
  • 8.9.3 Segmental and Regional Analysis
  • 8.9.4 Research & Development Expense
  • 8.9.5 Recent strategies and developments:
    • 8.9.5.1 Acquisition and Mergers:
  • 8.9.6 SWOT Analysis
• 8.10. Teva Pharmaceutical Industries Ltd.
  • 8.10.1 Company Overview
  • 8.10.2 Financial Analysis
  • 8.10.3 Regional Analysis
  • 8.10.4 Research & Development Expenses
  • 8.10.5 Recent strategies and developments:
    • 8.10.5.1 Product Launches and Product Expansions:
  • 8.10.6 SWOT Analysis

Chapter 9. Winning Imperatives for Conjunctivitis Treatment Market

관련자료